CanSino Biologics Inc.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 2009-01-13

Employees: 1.4K

Market Cap: -

Website: http://www.cansinotech.com

Introduction: The company was founded in 2009 in China. It is an industry-leading high-tech biological products company with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is an innovative vaccine enterprise dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The marketed products and product pipeline cover the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, and many other vaccine varieties with high clinical demand. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.

Clinical Trials

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Phase 3

Completed

Conditions: Tetanus

Interventions: Biological: TT
Biological: TTVA

First Posted Date: 2023-11-07

Last Posted Date: 2024-12-02

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 1000

Registration Number: NCT06120751

Locations: 🇨🇳
Center for Disease Control and Prevention, Qixingguan District, Bijie City, Bijie, Guizhou, China

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

Phase 1

Completed

Conditions: Poliomyelitis

Interventions: Biological: VLP-Polio
Biological: Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)
Biological: Inactivated poliomyelitis vaccine (IPOL)
Biological: IPOL

First Posted Date: 2023-10-26

Last Posted Date: 2024-12-04

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 72

Registration Number: NCT06101173

Locations: 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia

A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

Phase 1

Active, not recruiting

Conditions: Pertussis
Diphtheria
Tetanus

Interventions: Biological: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)
Biological: 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）
Biological: Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)

First Posted Date: 2023-09-28

Last Posted Date: 2025-04-03

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 180

Registration Number: NCT06056050

Locations: 🇨🇳
Shaanxi Center for Disease Control and Prevention, Xi'an, Shaanxi, China

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

Phase 3

Active, not recruiting

Conditions: Epidemic Meningitis

Interventions: Biological: MSPV4
Biological: MCV4

First Posted Date: 2023-08-25

Last Posted Date: 2025-03-21

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 1000

Registration Number: NCT06011200

Locations: 🇨🇳
Shanyang County Center for Disease Prevention and Control, Shanyang, Shanxi, China

A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Phase 1

Completed

Conditions: Herpes Zoster

Interventions: Biological: Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)
Biological: Zoster Vaccine Recombinant, Adjuvanted (Shingrix)
Biological: Shingrix
Biological: IH saline
Biological: ChAdOx1-VZV
Biological: IH ChAdOx1-VZV

First Posted Date: 2023-08-14

Last Posted Date: 2024-12-04

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 65

Registration Number: NCT05991427

Locations: 🇨🇦
Canadian Center for Vaccinology, Halifax, Canada

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Phase 3

Active, not recruiting

Conditions: Diphtheria, Tetanus and Acellular Pertussis

Interventions: Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)
Biological: DTcP
Biological: Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP
Biological: Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib
Biological: DTaP-IPV-Hib

First Posted Date: 2023-07-19

Last Posted Date: 2025-03-17

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 2520

Registration Number: NCT05951725

Locations: 🇨🇳
Changge Center for Disease Control and Prevention, Xuchang, Henan, China

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Phase 4

Active, not recruiting

Conditions: Epidemic Meningitis

Interventions: Biological: MCV4

First Posted Date: 2023-07-07

Last Posted Date: 2024-12-04

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 660

Registration Number: NCT05935176

Locations: 🇨🇳
Wuzhi County Center for Disease Control and Prevention, Jiaozuo, Henan, China

Clinical Trial of Recombinant Pneumococcal Protein Vaccine

Phase 1

Completed

Conditions: Pneumonia
Respiratory Tract Infections
Respiratory Tract Diseases

Interventions: Biological: PPV23
Biological: PBPV

First Posted Date: 2022-11-21

Last Posted Date: 2024-12-04

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 60

Registration Number: NCT05622942

Locations: 🇨🇳
Lancang Lahu Autonomous County Center for Disease Control and Prevention, Puer, Yunnan, China

IH Convidecia as Second Booster Dose Against Breakthrough Infections

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
Biological: mRNA vaccine BNT162b2 (Pfizer)

First Posted Date: 2022-08-26

Last Posted Date: 2023-09-08

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 540

Registration Number: NCT05517642

Locations: 🇲🇾
Hospital Ampang, Ampang, Selangor Darul Ehsan, Malaysia

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

Phase 3

Withdrawn

Conditions: COVID-19

Interventions: Biological: mRNA-based COVID-19 vaccine
Biological: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
Biological: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation

First Posted Date: 2022-07-05

Last Posted Date: 2023-06-18

Lead Sponsor: CanSino Biologics Inc.

Registration Number: NCT05442684

Home Terms & Conditions Privacy Policy